GRM1 and breast carcinoma: The in vivo treatment of the MDA-MB-231 xenograft model, with Riluzole used in a medical trial for breast cancer, inhibited tumor progression up to 50% in the 4T1 mice, as early as day 9 compared with the control, suggesting that mGluR1 can promote tumor growth through the regulation of angiogenesis (67).